China Neurodegenerative Drugs Market Report & Forecast 2021-2027

China Neurodegenerative Drugs Market Report & Forecast 2021-2027

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Neurodegenerative Drugs Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 China Neurodegenerative Drugs Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 China Neurodegenerative Drugs Overall Market Size
2.1 China Neurodegenerative Drugs Market Size: 2021 VS 2027
2.2 China Neurodegenerative Drugs Revenue, Prospects & Forecasts: 2016-2027
2.3 China Neurodegenerative Drugs Sales: 2016-2027
3 Company Landscape
3.1 Top Neurodegenerative Drugs Players in China Market
3.2 Top China Neurodegenerative Drugs Companies Ranked by Revenue
3.3 China Neurodegenerative Drugs Revenue by Companies
3.4 China Neurodegenerative Drugs Sales by Companies
3.5 China Neurodegenerative Drugs Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Neurodegenerative Drugs Companies in China Market, by Revenue in 2020
3.7 Manufacturers Neurodegenerative Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Neurodegenerative Drugs Players in China Market
3.8.1 List of Tier 1 Neurodegenerative Drugs Companies in China
3.8.2 List of Tier 2 and Tier 3 Neurodegenerative Drugs Companies in China
4 Sights by Type
4.1 Overview
4.1.1 By Type - China Neurodegenerative Drugs Market Size Markets, 2021 & 2027
4.1.2 NMDA
4.1.3 SSRIs
4.1.4 Dopamine Inhibitors
4.2 By Type - China Neurodegenerative Drugs Revenue & Forecasts
4.2.1 By Type - China Neurodegenerative Drugs Revenue, 2016-2021
4.2.2 By Type - China Neurodegenerative Drugs Revenue, 2022-2027
4.2.3 By Type - China Neurodegenerative Drugs Revenue Market Share, 2016-2027
4.3 By Type - China Neurodegenerative Drugs Sales & Forecasts
4.3.1 By Type - China Neurodegenerative Drugs Sales, 2016-2021
4.3.2 By Type - China Neurodegenerative Drugs Sales, 2022-2027
4.3.3 By Type - China Neurodegenerative Drugs Sales Market Share, 2016-2027
4.4 By Type - China Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - China Neurodegenerative Drugs Market Size, 2021 & 2027
5.1.2 Parkinson's Disease
5.1.3 Huntington Disease
5.1.4 Amyotrophic Lateral Sclerosis
5.1.5 Alzheimer's Disease
5.2 By Application - China Neurodegenerative Drugs Revenue & Forecasts
5.2.1 By Application - China Neurodegenerative Drugs Revenue, 2016-2021
5.2.2 By Application - China Neurodegenerative Drugs Revenue, 2022-2027
5.2.3 By Application - China Neurodegenerative Drugs Revenue Market Share, 2016-2027
5.3 By Application - China Neurodegenerative Drugs Sales & Forecasts
5.3.1 By Application - China Neurodegenerative Drugs Sales, 2016-2021
5.3.2 By Application - China Neurodegenerative Drugs Sales, 2022-2027
5.3.3 By Application - China Neurodegenerative Drugs Sales Market Share, 2016-2027
5.4 By Application - China Neurodegenerative Drugs Price (Manufacturers Selling Prices), 2016-2027
6 Manufacturers & Brands Profiles
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Overview
6.1.3 Novartis Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.1.4 Novartis Neurodegenerative Drugs Product Description
6.1.5 Novartis Recent Developments
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Overview
6.2.3 Pfizer Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.2.4 Pfizer Neurodegenerative Drugs Product Description
6.2.5 Pfizer Recent Developments
6.3 Merck Serono
6.3.1 Merck Serono Corporation Information
6.3.2 Merck Serono Overview
6.3.3 Merck Serono Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.3.4 Merck Serono Neurodegenerative Drugs Product Description
6.3.5 Merck Serono Recent Developments
6.4 Biogen Idec
6.4.1 Biogen Idec Corporation Information
6.4.2 Biogen Idec Overview
6.4.3 Biogen Idec Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.4.4 Biogen Idec Neurodegenerative Drugs Product Description
6.4.5 Biogen Idec Recent Developments
6.5 TEVA
6.5.1 TEVA Corporation Information
6.5.2 TEVA Overview
6.5.3 TEVA Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.5.4 TEVA Neurodegenerative Drugs Product Description
6.5.5 TEVA Recent Developments
6.6 UCB
6.6.1 UCB Corporation Information
6.6.2 UCB Overview
6.6.3 UCB Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.6.4 UCB Neurodegenerative Drugs Product Description
6.6.5 UCB Recent Developments
6.7 Boehringer Ingelheim
6.7.1 Boehringer Ingelheim Corporation Information
6.7.2 Boehringer Ingelheim Overview
6.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.7.4 Boehringer Ingelheim Neurodegenerative Drugs Product Description
6.7.5 Boehringer Ingelheim Recent Developments
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Overview
6.8.3 Sanofi Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.8.4 Sanofi Neurodegenerative Drugs Product Description
6.8.5 Sanofi Recent Developments
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Overview
6.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.9.4 GlaxoSmithKline Neurodegenerative Drugs Product Description
6.9.5 GlaxoSmithKline Recent Developments
6.10 Livzon Pharmaceutical
6.10.1 Livzon Pharmaceutical Corporation Information
6.10.2 Livzon Pharmaceutical Overview
6.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Description
6.10.5 Livzon Pharmaceutical Recent Developments
6.11 Haisco Pharmaceutical
6.11.1 Haisco Pharmaceutical Corporation Information
6.11.2 Haisco Pharmaceutical Overview
6.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Description
6.11.5 Haisco Pharmaceutical Recent Developments
6.12 Jingxin Pharmaceutical
6.12.1 Jingxin Pharmaceutical Corporation Information
6.12.2 Jingxin Pharmaceutical Overview
6.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Description
6.12.5 Jingxin Pharmaceutical Recent Developments
6.13 Dongcheng Biochemicals
6.13.1 Dongcheng Biochemicals Corporation Information
6.13.2 Dongcheng Biochemicals Overview
6.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Description
6.13.5 Dongcheng Biochemicals Recent Developments
6.14 Hisun Pharmaceutical
6.14.1 Hisun Pharmaceutical Corporation Information
6.14.2 Hisun Pharmaceutical Overview
6.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Description
6.14.5 Hisun Pharmaceutical Recent Developments
6.15 Luye Pharma
6.15.1 Luye Pharma Corporation Information
6.15.2 Luye Pharma Overview
6.15.3 Luye Pharma Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.15.4 Luye Pharma Neurodegenerative Drugs Product Description
6.15.5 Luye Pharma Recent Developments
6.16 Ark Pharmaceutical
6.16.1 Ark Pharmaceutical Corporation Information
6.16.2 Ark Pharmaceutical Overview
6.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.16.4 Ark Pharmaceutical Neurodegenerative Drugs Product Description
6.16.5 Ark Pharmaceutical Recent Developments
6.17 Kanghong Pharmaceutical
6.17.1 Kanghong Pharmaceutical Corporation Information
6.17.2 Kanghong Pharmaceutical Overview
6.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Description
6.17.5 Kanghong Pharmaceutical Recent Developments
6.18 Huahai Pharmaceutical
6.18.1 Huahai Pharmaceutical Corporation Information
6.18.2 Huahai Pharmaceutical Overview
6.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Description
6.18.5 Huahai Pharmaceutical Recent Developments
6.19 BORA PHARMACEUTICALS
6.19.1 BORA PHARMACEUTICALS Corporation Information
6.19.2 BORA PHARMACEUTICALS Overview
6.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales and Revenue in China Market (2016-2021)
6.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Description
6.19.5 BORA PHARMACEUTICALS Recent Developments
7 China Neurodegenerative Drugs Production Capacity, Analysis
7.1 China Neurodegenerative Drugs Production Capacity, 2016-2027
7.2 Neurodegenerative Drugs Production Capacity of Key Manufacturers in China Market
8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints
9 Neurodegenerative Drugs Supply Chain Analysis
9.1 Neurodegenerative Drugs Industry Value Chain
9.2 Neurodegenerative Drugs Upstream Market
9.3 Neurodegenerative Drugs Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Neurodegenerative Drugs Distributors and Sales Agents in China Market
10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer
List of Tables
Table 1. Key Players of Neurodegenerative Drugs in China Market
Table 2. Top Neurodegenerative Drugs Players in China Market, Ranking by Revenue (2019)
Table 3. China Neurodegenerative Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 4. China Neurodegenerative Drugs Revenue Share by Companies, 2016-2021
Table 5. China Neurodegenerative Drugs Sales by Companies, (K Units), 2016-2021
Table 6. China Neurodegenerative Drugs Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Neurodegenerative Drugs Price (2016-2021) & (US$/Unit)
Table 8. Manufacturers Neurodegenerative Drugs Product Type
Table 9. List of Tier 1 Neurodegenerative Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Neurodegenerative Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. Major Manufacturers of NMDA
Table 12. Major Manufacturers of SSRIs
Table 13. By Type - China Neurodegenerative Drugs Revenue, (US$, Mn), 2021 & 2027
Table 14. By Type - China Neurodegenerative Drugs Revenue (US$, Mn), 2016-2021
Table 15. By Type - China Neurodegenerative Drugs Revenue (US$, Mn), 2022-2027
Table 16. By Type - China Neurodegenerative Drugs Sales (K Units), 2016-2021
Table 17. By Type - China Neurodegenerative Drugs Sales (K Units), 2022-2027
Table 18. By Application - China Neurodegenerative Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 19. By Application - China Neurodegenerative Drugs Revenue (US$, Mn), 2016-2021
Table 20. By Application - China Neurodegenerative Drugs Revenue (US$, Mn), 2022-2027
Table 21. By Application - China Neurodegenerative Drugs Sales (K Units), 2016-2021
Table 22. By Application - China Neurodegenerative Drugs Sales (K Units), 2022-2027
Table 23. Novartis Corporation Information
Table 24. Novartis Description and Major Businesses
Table 25. Novartis Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 26. Novartis Neurodegenerative Drugs Product
Table 27. Novartis Recent Developments
Table 28. Pfizer Corporation Information
Table 29. Pfizer Description and Major Businesses
Table 30. Pfizer Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 31. Pfizer Neurodegenerative Drugs Product
Table 32. Pfizer Recent Developments
Table 33. Merck Serono Corporation Information
Table 34. Merck Serono Description and Major Businesses
Table 35. Merck Serono Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 36. Merck Serono Neurodegenerative Drugs Product
Table 37. Merck Serono Recent Developments
Table 38. Biogen Idec Corporation Information
Table 39. Biogen Idec Description and Major Businesses
Table 40. Biogen Idec Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 41. Biogen Idec Neurodegenerative Drugs Product
Table 42. Biogen Idec Recent Developments
Table 43. TEVA Corporation Information
Table 44. TEVA Description and Major Businesses
Table 45. TEVA Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 46. TEVA Neurodegenerative Drugs Product
Table 47. TEVA Recent Developments
Table 48. UCB Corporation Information
Table 49. UCB Description and Major Businesses
Table 50. UCB Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 51. UCB Neurodegenerative Drugs Product
Table 52. UCB Recent Developments
Table 53. Boehringer Ingelheim Corporation Information
Table 54. Boehringer Ingelheim Description and Major Businesses
Table 55. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 56. Boehringer Ingelheim Neurodegenerative Drugs Product
Table 57. Boehringer Ingelheim Recent Developments
Table 58. Sanofi Corporation Information
Table 59. Sanofi Description and Major Businesses
Table 60. Sanofi Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 61. Sanofi Neurodegenerative Drugs Product
Table 62. Sanofi Recent Developments
Table 63. GlaxoSmithKline Corporation Information
Table 64. GlaxoSmithKline Description and Major Businesses
Table 65. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 66. GlaxoSmithKline Neurodegenerative Drugs Product
Table 67. GlaxoSmithKline Recent Developments
Table 68. Livzon Pharmaceutical Corporation Information
Table 69. Livzon Pharmaceutical Description and Major Businesses
Table 70. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 71. Livzon Pharmaceutical Neurodegenerative Drugs Product
Table 72. Livzon Pharmaceutical Recent Developments
Table 73. Haisco Pharmaceutical Corporation Information
Table 74. Haisco Pharmaceutical Description and Major Businesses
Table 75. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 76. Haisco Pharmaceutical Neurodegenerative Drugs Product
Table 77. Haisco Pharmaceutical Recent Developments
Table 78. Jingxin Pharmaceutical Corporation Information
Table 79. Jingxin Pharmaceutical Description and Major Businesses
Table 80. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 81. Jingxin Pharmaceutical Neurodegenerative Drugs Product
Table 82. Jingxin Pharmaceutical Recent Developments
Table 83. Dongcheng Biochemicals Corporation Information
Table 84. Dongcheng Biochemicals Description and Major Businesses
Table 85. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 86. Dongcheng Biochemicals Neurodegenerative Drugs Product
Table 87. Dongcheng Biochemicals Recent Developments
Table 88. Hisun Pharmaceutical Corporation Information
Table 89. Hisun Pharmaceutical Description and Major Businesses
Table 90. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 91. Hisun Pharmaceutical Neurodegenerative Drugs Product
Table 92. Hisun Pharmaceutical Recent Developments
Table 93. Luye Pharma Corporation Information
Table 94. Luye Pharma Description and Major Businesses
Table 95. Luye Pharma Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 96. Luye Pharma Neurodegenerative Drugs Product
Table 97. Luye Pharma Recent Developments
Table 98. Ark Pharmaceutical Corporation Information
Table 99. Ark Pharmaceutical Description and Major Businesses
Table 100. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 101. Ark Pharmaceutical Neurodegenerative Drugs Product
Table 102. Ark Pharmaceutical Recent Developments
Table 103. Kanghong Pharmaceutical Corporation Information
Table 104. Kanghong Pharmaceutical Description and Major Businesses
Table 105. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 106. Kanghong Pharmaceutical Neurodegenerative Drugs Product
Table 107. Kanghong Pharmaceutical Recent Developments
Table 108. Huahai Pharmaceutical Corporation Information
Table 109. Huahai Pharmaceutical Description and Major Businesses
Table 110. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 111. Huahai Pharmaceutical Neurodegenerative Drugs Product
Table 112. Huahai Pharmaceutical Recent Developments
Table 113. BORA PHARMACEUTICALS Corporation Information
Table 114. BORA PHARMACEUTICALS Description and Major Businesses
Table 115. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021)
Table 116. BORA PHARMACEUTICALS Neurodegenerative Drugs Product
Table 117. BORA PHARMACEUTICALS Recent Developments
Table 118. Neurodegenerative Drugs Production Capacity (K Units) of Key Manufacturers in China Market, 2019-2021 (K Units)
Table 119. China Neurodegenerative Drugs Capacity Market Share of Key Manufacturers, 2019-2021
Table 120. Neurodegenerative Drugs Market Opportunities & Trends in China Market
Table 121. Neurodegenerative Drugs Market Drivers in China Market
Table 122. Neurodegenerative Drugs Market Restraints in China Market
Table 123. Neurodegenerative Drugs Raw Materials
Table 124. Neurodegenerative Drugs Raw Materials Suppliers in China Market
Table 125. Typical Neurodegenerative Drugs Downstream
Table 126. Neurodegenerative Drugs Downstream Clients in China Market
Table 127. Neurodegenerative Drugs Distributors and Sales Agents in China Market
List of Figures
Figure 1. Neurodegenerative Drugs Product Picture
Figure 2. Neurodegenerative Drugs Segment by Type
Figure 3. Neurodegenerative Drugs Segment by Application
Figure 4. China Neurodegenerative Drugs Market Overview: 2020
Figure 5. China Neurodegenerative Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. China Neurodegenerative Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. Neurodegenerative Drugs Sales in China Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Neurodegenerative Drugs Revenue in 2020
Figure 9. NMDA Product Picture
Figure 10. SSRIs Product Picture
Figure 11. Dopamine Inhibitors Product Picture
Figure 12. By Type - China Neurodegenerative Drugs Sales Market Share, 2016-2027
Figure 13. By Type - China Neurodegenerative Drugs Revenue Market Share, 2016-2027
Figure 14. By Type - China Neurodegenerative Drugs Price (US$/Unit), 2016-2027
Figure 15. Parkinson's Disease
Figure 16. Huntington Disease
Figure 17. Amyotrophic Lateral Sclerosis
Figure 18. Alzheimer's Disease
Figure 19. By Application - China Neurodegenerative Drugs Sales Market Share, 2016-2027
Figure 20. By Application - China Neurodegenerative Drugs Revenue Market Share, 2016-2027
Figure 21. By Application - China Neurodegenerative Drugs Price (US$/Unit), 2016-2027
Figure 22. Novartis Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 23. Pfizer Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 24. Merck Serono Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 25. Biogen Idec Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 26. TEVA Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 27. UCB Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 28. Boehringer Ingelheim Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 29. Sanofi Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 30. GlaxoSmithKline Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 31. Livzon Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 32. Haisco Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 33. Jingxin Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 34. Dongcheng Biochemicals Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 35. Hisun Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 36. Luye Pharma Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 37. Ark Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Kanghong Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Huahai Pharmaceutical Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. BORA PHARMACEUTICALS Neurodegenerative Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. China Neurodegenerative Drugs Production Capacity (K Units), 2016-2027
Figure 42. Neurodegenerative Drugs Industry Value Chain
Figure 43. Marketing Channels

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs